NEUROBiOGEN

본문 바로가기 주메뉴 바로가기

Comunications

NEUROBIOGEN has been working with an advisory network of researchers and clinical
experts specializing in brain & neurological diseases with long experience.

News

News
Notice

News

Here are news on NEUROBIOGEN (currently in Korean only).

NO	SUBJECT	DATE	VIEW
117	Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to	2025. 01. 07	31
116	Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation	2024. 12. 17	45
115	Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025	2024. 12. 16	76
114	Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Tria	2024. 12. 16	40
113	Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neur	2024. 12. 16	136
112	Neurobiogen's Technology for Obesity Treatment is Fastening...	2024. 12. 13	50
111	Neurobiogen enters into Licensing Agreement with U.S. pharmaceutical companies for dementia and obesity drugs	2024. 12. 12	70
110	Scilex Bio Enters into Licensing Agreement with Neurobiogen	2024. 12. 12	50
109	CNR Research Performs Neurobiogen's Alzheimer's and Obesity Treatments Clinical Trials Phase2a	2024. 09. 20	114
108	CNR Research and Neurobiogen, Alzheimer's and Obesity Treatments Approved by the Ministry of Food and Drug Safety.	2024. 09. 19	110

1 2 3 4 5